Arbutus Biopharma Corp (ABUS)vsModerna Inc (MRNA)
ABUS
Arbutus Biopharma Corp
$4.32
+0.70%
HEALTHCARE · Cap: $646.82M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 1126% more annual revenue ($2.23B vs $181.72M). ABUS leads profitability with a 84.2% profit margin vs -141.4%. ABUS earns a higher WallStSmart Score of 44/100 (D).
ABUS
Hold44
out of 100
Grade: D
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABUS.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 59 in profit
Keeps 84 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 90.6%
Negative free cash flow — burning cash
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABUS
The strongest argument for ABUS centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 84.2% and operating margin at -567.0%.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ABUS
The primary concerns for ABUS are EPS Growth, Market Cap, Revenue Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ABUS profiles as a declining stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ABUS generates stronger free cash flow (-12M), providing more financial flexibility.
Bottom Line
ABUS scores higher overall (44/100 vs 21/100), backed by strong 84.2% margins. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arbutus Biopharma Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?